Saprami Technology

Saprami Technology is a biotechnology company specializing in the discovery and development of molecular glues for targeted protein degradation. Founded by Dr. Benjamin Ebert and Dr. Mikko Taipale, the company leverages deep expertise in E3 ligase biology and protein homeostasis to target previously undruggable proteins. Their proprietary platform identifies small molecules that induce novel interactions between E3 ubiquitin ligases and disease-relevant proteins, leading to their degradation. Saprami is currently in the pre-clinical stage, with a primary focus on developing transformative therapies for oncology and hematologic malignancies. The company is backed by prominent life science investors and operates out of the Boston biotechnology hub.